Home › Type 2 Diabetes › Oklahoma
Pag-aaral pangklinika para sa Type 2 Diabetes sa Oklahoma
13 pag-aaral para sa Type 2 Diabetes ang naghahanap ng mga kalahok sa mga site sa Oklahoma.
Mga Lungsod sa Oklahoma
Opisyal na teksto ng pag-aaral (English)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Tekton Research Oklahoma City, Oklahoma City
- South Oklahoma Heart Research Group, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07064473A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- Tekton Research Oklahoma City, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07754461A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Hightower Clinical, Oklahoma City
- Medical Research International, LLC, Oklahoma City
- Ascension St. John - Jane Phillips Medical Center, Tulsa
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 55 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06112418A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT07743450A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
- Unity Clinical Research, Oklahoma City
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07340320A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06897475A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Oklahoma City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07662213AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Lynn Institute of Norman, Norman
Nagre-recruitPhase 3
Edad 45 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07797335A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Research Site, Norman
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT07662109A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitPhase 3
Edad 10 hanggang 17 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06739122DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
- The University of Oklahoma Health Sciences Center, Oklahoma City
Nagre-recruitObservasyonal na pag-aaral
Edad 8 hanggang 15 · Lahat ng kasarian · Na-update May 7, 2026 · NCT06525259Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
- Lynn Health Science Institute - Oklahoma City, Oklahoma City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 18, 2026 · NCT07282743Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.